Avenues Pharma Distributors Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 08-07-2024
- Paid Up Capital ₹ 0.10 M
as on 08-07-2024
- Company Age 5 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 35.00 Cr
as on 08-07-2024
- Revenue 16.81%
(FY 2022)
- Profit 153.46%
(FY 2022)
- Ebitda 42.01%
(FY 2022)
- Net Worth 213.24%
(FY 2022)
- Total Assets -1.80%
(FY 2022)
About Avenues Pharma Distributors
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹35.00 Cr.
Prabhat Agrawal, Siddharth Upadhyay, and Muniswamy Gautham serve as directors at the Company.
- CIN/LLPIN
U24239KA2019PTC122720
- Company No.
122720
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
26 Mar 2019
- Date of AGM
04 Aug 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangalore, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Avenues Pharma Distributors?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Prabhat Agrawal  | Director | 15-Apr-2019 | Current |
| Siddharth Upadhyay | Additional Director | 11-Aug-2023 | Current |
| Muniswamy Gautham | Director | 05-Nov-2019 | Current |
Financial Performance and Corporate Structure Insights of Avenues Pharma Distributors.
Avenues Pharma Distributors Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 16.81% increase. The company also saw a substantial improvement in profitability, with a 153.46% increase in profit. The company's net worth Soared by an impressive increase of 213.24%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Avenues Pharma Distributors?
In 2022, Avenues Pharma Distributors had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
R S M Pharma Private LimitedActive 35 years 8 monthsPrabhat Agrawal, Siddharth Upadhyay and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 08 Jan 2020 | ₹35.00 Cr | Open |
How Many Employees Work at Avenues Pharma Distributors?
Avenues Pharma Distributors has a workforce of 202 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Avenues Pharma Distributors, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Avenues Pharma Distributors's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
